In the competitive world of RNA-based therapeutics, the efficiency of lipid nanoparticles (LNPs) is a critical factor for the clinical translation of vaccines and genetic therapeutics. However, the discovery of new ionizable lipids capable of maximizing cellular transfection remains a bottleneck. In this context, artificial intelligence and machine learning models have emerged as promising tools to directly predict transfection yield from the lipid chemical structure, enabling high-throughput virtual screenings. However, the proliferation of models without a standardized evaluation framework generates uncertainty about their reliability. This article analyzes the need for rigorous benchmarking and how companies can rely on custom applications and custom software to implement these solutions with guarantees.
Efficient delivery of messenger RNA or RNA interference via LNP depends on the ability of the ionizable lipid to facilitate entry into the cell cytoplasm. Until recently, the optimization of these lipids was based on expensive and time-consuming experimental trials. Artificial intelligence has been a game-changer: models such as neural networks, graph-based methods, or traditional approaches can learn the complex relationship between molecular structure and transfection efficiency. However, the scientific community has observed that many published models are not compared under homogeneous conditions, which makes it difficult to identify which one is truly superior. This is where the importance of a robust, transparent and reproducible benchmarking framework arises, which allows researchers and companies in the pharmaceutical sector to make informed decisions.
A standardized assessment framework should include at least three key components: a curated and diverse dataset, multiple molecular representations (from classical descriptors to graph embeddings), and a battery of